BEAM vs VRTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BEAM · Beam Therapeutics$20.90 ▼ 0.19%
VRTX · Vertex Pharmaceuticals$515.02 ▼ 1.08%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BEAM -11.5%
- VRTX +21.5%
Head to head
| Metric | BEAM | VRTX |
|---|---|---|
| Price | $20.90 | $515.02 |
| Change today | ▼ 0.19% | ▼ 1.08% |
| Market cap | $2.16B | $130.58B |
| Return, 3 months | -26.2% | -5.9% |
| Return, year to date | -24.6% | +13.6% |
| Return, 1 year | -5.9% | +20.7% |
| P/E (TTM) | – | 33.1 |
| P/B | 2.3 | 6.2 |
| P/E percentile vs own 5y | 15th | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -96.8% | +11.8% |
| Net profit growth (YoY) | -19.4% | -39.6% |
| Gross margin | – | 85.5% |
| Operating margin | -267.7% | 33.1% |
| Net margin | -73.9% | 30.7% |
| Return on equity | -11.3% | 20.8% |
| Analyst target vs. price | +136.2% | +21.1% |
| Analyst buy share | 92% | 95% |
| RSI (14) | 36 | 41 |
| 30-day volatility | 76.9% | 32.0% |
| Max drawdown, 1 year | -45.5% | -15.2% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VRTX is the largest of the group by market value.
- VRTX has returned the most over the past year.
- VRTX is growing revenue fastest.
- VRTX keeps the most profit per dollar of sales.
- VRTX has been the calmest stock over the last 30 days.